Rebound in community antibiotic consumption after the observed decrease during the COVID-19 pandemic, EU/EEA, 2022
Cèlia Ventura-Gabarró, Vivian Leung, Vera Vlahović–Palčevski, Anna Machowska, Dominique L. Monnet, Liselotte Diaz Högberg, ESAC-Net study group
Abstract
We observed a rebound in consumption of antibacterials for systemic use (ATC J01) in the community sector in the European Union/European Economic Area during 2021 and 2022, after an observed decrease between 2019 and 2020. The rates in 2022 returned to pre-COVID-19-pandemic levels and were exceeded in 13 countries. Although these patterns could partly be a result of changes in disease transmission during the study period, it could also reflect a lost opportunity to strengthen and reinforce prudent antibiotic use.
Topics & Concepts
Coronavirus disease 2019 (COVID-19)PandemicEuropean unionConsumption (sociology)2019-20 coronavirus outbreakTransmission (telecommunications)Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)AntibioticsEu countriesEuropean communityEnvironmental healthMedicineDiseaseEconomicsInfectious disease (medical specialty)Economic policyVirologyInternational tradeBiologyInternal medicineOutbreakEngineeringSocial scienceElectrical engineeringMicrobiologySociologyAntibiotic Use and ResistanceCOVID-19 epidemiological studiesHIV, Drug Use, Sexual Risk